GE Healthcare said that three studies utilizing its DaTscan tracer and investigational imaging agent flutemetamol will be presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting.
Two company papers (publications 191 and 1781) will be presented on the use of DaTscan (ioflupane iodine-123 injection) in parkinsonian syndromes, while a third (publication 302) will compare automated quantification of F-18 flutemetamol data with a standard of truth based on histopathology, according to GE.
